Knowledge, Attitudes, and Practices: Preventing Delayed CINV with Antiemetics
Abstract
Introduction: Chemotherapy-induced nausea and vomiting (CINV) is the most feared side effect by cancer patients. To prevent and minimize the occurrence of delayed CINV, patients are given post-chemotherapy antiemetics. Adequate patient knowledge is essential for promoting awareness of CINV and the appropriate use of post-chemotherapy antiemetics. This study examines the knowledge, attitudes, and practice of cancer patients towards the occurrence of delayed CINV and the use of post-chemotherapy antiemetics.
Methods: Descriptive cross-sectional study conducted in the chemotherapy room at Hospital X, South Kalimantan, Indonesia. The study was conducted in September-November 2024. Face-to-face interviews guided by a structured questionnaire were conducted on 114 cancer patients.
Results: The study revealed that patient knowledge regarding the side effects of CINV and the use of post-chemotherapy antiemetics was generally limited. Specifically, 49 respondents (43%) demonstrated a basic level of knowledge, 35 respondents (30.7%) showed sufficient knowledge, and 30 respondents (26.3%) exhibited good knowledge. Patients with higher education levels demonstrated significantly higher scores in both the attitude domain (3.31 ± 1.277) and the practice domain (3.75 ± 1.223).
Conclusion: Healthcare professionals play a crucial role in educating patients on the appropriate use of antiemetic medications. Effective education aims to enhance chemotherapy patients' knowledge, attitudes, and practices regarding the use of post-chemotherapy antiemetics.
References
Feyer P, Jahn F, Jordan K. Prophylactic Management of Radiation-Induced Nausea and Vomiting. Biomed Res Int. 2015;2015:893013. doi: 10.1155/2015/893013. Available from: https://onlinelibrary.wiley.com/doi/10.1155/2015/893013
Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260-7. doi: 10.1093/annonc/mdx100. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)32429-9/fulltext
Tsubata Y, Nakao M, Amano Y, Hotta T, Hamaguchi M, Okimoto T, Miura K, Hamaguchi S, Kuraki T, Itakura M, Isobe T. Translational and Randomized Study of 5-HT3 Receptor Antagonists for Evaluation of Chemotherapy-induced Nausea and Vomiting Related Biomarkers. J Med Invest. 2019;66(3.4):269-74. doi: 10.2152/jmi.66.269. Available from: https://www.jstage.jst.go.jp/article/jmi/66/3.4/66_269/_article
Manson E, Routledge PA. Nausea and vomiting. In: Walker R, Whittlesia C, editors. Clinical Pharmacy and Therapeutics. 5th ed. China: Churchill Livingstone Elsevier; 2012. pp. 535–44.
Baburaj G, Abraham AM, George L, Shetty V, Thempalangad RM, Rajesh KS, Raj KCB. A Study on Utilization and Evaluation of Antiemetics in Chemotherapy-induced Nausea and Vomiting. Indian J Med Paediatr Oncol. 2017;38(3):334-9. doi: 10.4103/ijmpo.ijmpo_116_17. Available from: https://www.thieme-connect.com/products/ejournals/abstract/10.4103/ijmpo.ijmpo_116_17
Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJG, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107-17. doi: 10.1007/s00520-010-1073-9. Available from: https://link.springer.com/article/10.1007/s00520-010-1073-9
Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, Barrio PD, Tornamira MV. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer. 2015;23(9):2833-40. doi: 10.1007/s00520-015-2809-3. Available from: https://link.springer.com/article/10.1007/s00520-015-2809-3
Sari RP, Prenggono MD, Putra AMP, Atmaja DS, Rahmadi M, Suharjono. The efficacy of combining ondansetron with dexamethasone in delayed chemotherapy-induced nausea and vomiting. Pharm Educ. 2024;24(3):211–5. doi: 10.46542/pe.2024.243.211215. Available from: https://pharmacyeducation.fip.org/pharmacyeducation/article/view/2703
Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021;26:100278. doi: 10.1016/j.ctarc.2020.100278. Available from: https://www.sciencedirect.com/science/article/pii/S2468294220301131?via%3Dihub
Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2012;5(4):232-40. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4046471/
Chan A, Low XH, Yap KYL. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm. 2012;18(5):385-94. doi: 10.18553/jmcp.2012.18.5.385. Available from: https://pmc.ncbi.nlm.nih.gov/articles/pmid/22663171/
Vidall C, Sharma S, Amlani B. Patient-practitioner perception gap in treatment-induced nausea and vomiting, Br J Nurs. 2016;25(16):S4–S11. doi: 10.12968/bjon.2016.25.s4. Available from: https://www.magonlinelibrary.com/doi/abs/10.12968/bjon.2016.25.S4?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Barbor, M. Role of Pharmacists in the Management of Chemotherapy-Induced Nausea and Vomiting. J Hematol Oncol Pharm. 2019;9(2):17788. Available from: https://jhoponline.com/issue-archive/2019-issues/jhop-june-2019-vol-9-no-2/17788:role-of-pharmacists-in-the-management-of-chemotherapy-induced-nausea-and-vomiting
Lively A, Minard LV, Scott S, Deal H, Lambourne T, Giffin J. Exploring the perspectives of healthcare professionals in delivering optimal oncology medication education. PLoS One. 2020;15(2):e0228571. doi: 10.1371/journal.pone.0228571. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228571
Rapoport BL. Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front Pharmacol. 2017;8:19. doi: 10.3389/fphar.2017.00019. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00019/full
Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist. 2021 Jun;26(6):e1073-e1082. doi: 10.1002/onco.13716. Available from: https://academic.oup.com/oncolo/article/26/6/e1073/6520983
Gebre D, Murugan R, Bizuwork K, Wurjine TH. Knowledge, practice and perceived barriers towards chemotherapy induced nausea and vomiting in prophylaxis guideline adherence among nurses in oncology units at selected hospitals, in Addis Ababa, Ethiopia, a cross-sectional study. BMC Nurs. 2022;21(1):223. doi: 10.1186/s12912-022-01009-7. Available from: https://bmcnurs.biomedcentral.com/articles/10.1186/s12912-022-01009-7
Salsman JM, Grunberg SM, Beuamont JL, Rogers M, Paul D, Clayman ML, Cella D. Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives. J Natl Compr Canc Netw. 2012;10(2):149-57. doi: 10.6004/jnccn.2012.0018. Available from: https://jnccn.org/view/journals/jnccn/10/2/article-p149.xml
Kaupp K, Scott S, Minard LV, Lambourne T. Optimizing patient education of oncology medications: A quantitative analysis of the patient perspective. J Oncol Pharm Pract. 2019;25(6):1445-55. doi: 10.1177/1078155219843675. Available from: https://journals.sagepub.com/doi/10.1177/1078155219843675
Rha SY, Song SK, Lee CE, Park Y, Lee J. Gaps exist between patients’ experience and clinicians’ awareness of symptoms after chemotherapy: CINV and accompanying symptoms. Support Care Cancer. 2016;24(11):4559-66. doi: 10.1007/s00520-016-3295-y. Available from: https://link.springer.com/article/10.1007/s00520-016-3295-y
Lambourne T, Minard LV, Deal H, Pitman J, Rolle M, Saulnier D, Houlihan J. Optimizing Patient Education of Oncology Medications: A Patient Perspective. J Cancer Educ. 2019;34(5):1024-30. doi: 10.1007/s13187-018-1406-9. Available from: https://link.springer.com/article/10.1007/s13187-018-1406-9
Lorusso V. Management of chemotherapy-induced nausea and vomiting by risk profile: Role of netupitant/palonosetron. Ther Clin Risk Manag. 2016;12:917-25. doi: 10.2147/TCRM.S89215. Available from: https://www.dovepress.com/article/download/27310
Crespo A, Tyszka M. Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract. 2017;23(4):243-8. doi: 10.1177/1078155216634180. Available from: https://journals.sagepub.com/doi/10.1177/1078155216634180
Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S. Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. Support Care Cancer. 2018;26(6):1841-9. doi: 10.1007/s00520-017-4004-1. Available from: https://link.springer.com/article/10.1007/s00520-017-4004-1
Wang Y, Wu H, Xu F. Impact of Clinical Pharmacy Services on KAP and QOL in Cancer Patients: A Single-Center Experience. Biomed Res Int. 2015;2015:502431. doi: 10.1155/2015/502431. Available from: https://onlinelibrary.wiley.com/doi/10.1155/2015/502431
Copyright (c) 2026 Journal of Public Health and Pharmacy
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with Journal of Public Health and Pharmacy retain the copyright of their work. The journal applies a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which grants the following rights:
-
Copyright Retention: Authors retain the copyright of their work, maintaining full control over their intellectual property without restrictions.
-
Right of First Publication: Authors grant the journal the right of first publication of their work. This ensures that the work is initially published and credited in Journal of Public Health and Pharmacy.
-
License to Share and Reuse: The work is licensed under CC BY-SA 4.0, allowing others to copy, distribute, remix, and build upon the work for any purpose, even commercially, as long as proper credit is given to the authors, and any new creations are licensed under the same terms.
